Statin-like drugs for the treatment of brain cholesterol loss in Alzheimer's disease

Current Drug Safety

Volumn 2, Issue 3, 2007, Pages 173-176

  Elisa, Biondi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Alzheimer's disease; Cholesterol; Rafts; Statins

Indexed keywords

ABC TRANSPORTER A1; ALPHA SECRETASE; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; ATORVASTATIN; BETA SECRETASE; CHOLESTEROL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYCLODEXTRIN; FLUINDOSTATIN; GAMMA SECRETASE; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; OXYGEN; PRAVASTATIN; SELADIN 1; SIMVASTATIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOPSY; BRAIN OXYGEN CONSUMPTION; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEATH; DEMENTIA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME SYNTHESIS; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HELPLESSNESS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; MEMBRANE FLUIDITY; NERVE CELL; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; PATIENT CARE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NERVE TISSUE PROTEINS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 35348824893     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607781668927     Document Type: Review

References (21)

1. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-43.
2. Mauch DH, Nagler K, Shumacher S. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001; 294: 1354-7.
3. Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004; 45: 1375-97.
4. Haines TH. Do sterols reduce proton and sodium leaks through lipid bilayers? Prog Lipid Res 2001; 40: 299-324.
5. Xie C, Turley SD, Dietscy JM. Cholesterol accumulation in tissues of the Niemann-pick type C mouse is determined by the rate of lipoprotein-cholesterol uptake through the coated-pit pathway in each organ. Proc Natl Acad Sci USA 1999; 96: 11992-7.
6. Dietschy JM, Turley SD. Control of cholesterol turnover in the mouse. J Biol Chem 2002; 277: 3801-4.
7. Lund EG, Xie C, Kotti T. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 2003; 278: 22980-8.
8. Vauthey C, de Freitas GR, van Melle G. Better outcome after stroke with higher serum cholesterol levels. Neurology 2000; 54: 1944-9.
9. Simons K, Keller P, De Strooper B. Cholesterol depletion inhibits the generation of beta- amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95: 6460-4.
10. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003; 160: 113-23.
11. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003; 100: 11735-40.
12. Greeve I, Hermans-Borgmayer I, Brellinger C. The human DI-MINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000; 20: 7345-52.
13. Ledesma MD, Da Silva JS, Shevchenko A. Proteomic characterisation of neuronal sphingolipid cholesterol microdomains: role in plasminogen activation. Brain Res 2003; 987: 107-16.
14. Abad-Rodriguez J, Ledesma MD, Craessaerts K. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004; 167: 953-60.
15. Ledesma MD, Abad-Rodriguez J, Galvan C. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep 2003; 4: 1190-6.
16. Sparks DL, Connor DJ, Browne PJ. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging 2002; 6: 324-31.
17. Fassbender K, Masters C, Beyreuther K. Alzheimer's disease: molecular concepts and therapeutic targets. Naturwissenschaften 2001; 88: 261-7.
18. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001; 187: 81-9.
19. Waters D, Higginson L, Gladstone P. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-68.
20. Shafig N, Malhotra S, Pandhi P. The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst. J Negat Results Biomed 2005; 4: 3.
21. Cole SL, Grudzien A, Manhart IO. Statins cause intracellular accumulation of amyloid precursorprotein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 2005; 280: 18755-70.